Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Scott Lish Sells 23,183 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Scott Lish sold 23,183 shares of the firm’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $12.03, for a total value of $278,891.49. Following the sale, the chief operating officer now owns 844,494 shares of the company’s stock, valued at $10,159,262.82. This represents a 2.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Scott Lish also recently made the following trade(s):

• On Thursday, February 6th, Scott Lish sold 27,453 shares of Alphatec stock. The stock was sold at an average price of $11.49, for a total transaction of $315,434.97.

Alphatec Price Performance

Shares of NASDAQ:ATEC opened at $12.53 on Friday. Alphatec Holdings, Inc. has a one year low of $4.88 and a one year high of $14.88. The stock has a fifty day moving average of $10.63 and a 200-day moving average of $8.37. The company has a market capitalization of $1.78 billion, a PE ratio of -9.79 and a beta of 1.43. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32.

Alphatec (NASDAQ:ATEC) last released its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). The business had revenue of $176.79 million during the quarter, compared to analysts’ expectations of $172.74 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. As a group, equities analysts anticipate that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Piper Sandler increased their price target on shares of Alphatec from $12.00 to $13.00 and gave the stock an “overweight” rating in a research report on Thursday. Barclays increased their price target on shares of Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 22nd. Needham & Company LLC reissued a “buy” rating and issued a $16.00 target price on shares of Alphatec in a report on Thursday. StockNews.com raised shares of Alphatec from a “sell” rating to a “hold” rating in a report on Friday. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Alphatec in a report on Tuesday, January 14th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $17.67.

Hedge Funds Weigh In On Alphatec

A number of hedge funds have recently modified their holdings of ATEC. Creative Planning increased its stake in shares of Alphatec by 83.9% in the third quarter. Creative Planning now owns 48,611 shares of the medical technology company’s stock worth $270,000 after acquiring an additional 22,171 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in shares of Alphatec by 30.1% in the third quarter. Assenagon Asset Management S.A. now owns 40,486 shares of the medical technology company’s stock worth $225,000 after acquiring an additional 9,361 shares during the last quarter. Stephens Inc. AR increased its position in Alphatec by 51.4% during the third quarter. Stephens Inc. AR now owns 21,743 shares of the medical technology company’s stock worth $121,000 after buying an additional 7,382 shares during the last quarter. Van ECK Associates Corp increased its position in Alphatec by 57.0% during the third quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company’s stock worth $99,000 after buying an additional 6,998 shares during the last quarter. Finally, Fernwood Investment Management LLC increased its position in Alphatec by 28.6% during the third quarter. Fernwood Investment Management LLC now owns 91,287 shares of the medical technology company’s stock worth $508,000 after buying an additional 20,300 shares during the last quarter. 66.35% of the stock is owned by institutional investors and hedge funds.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.